Shasqi presents two posters on their lead candidate, SQ3370, at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting.
In their trial-in-progress poster, Shasqi presents a first-in-human phase I study for their lead candidate SQ3370, a click activated protodrug therapy, in patients with advanced solid tumors. SQ3370 is the first click chemistry-based treatment to be used in humans. The study SQ3370-001 is currently enrolling patients with advanced solid tumors in the United States and Australia (ClinicalTrials.gov Identifier NCT04106492).
In another poster, Shasqi presents preclinical data on SQ3370. The findings show that SQ3370 induces a dose-dependent, sustained local and systemic anti-tumor response in two dual-tumor syngeneic mouse models. Additional pharmacological outcomes in the data suggest an immune mediated mechanism which could be further enhanced by checkpoint blockers. The treatment also demonstrated a favorable toxicity profile as it did not induce body weight losses, even at the highest administered dose.
